KRAS and neoplasm: WT1 has been reported to be a critical regulator of proliferation downstream of oncogenic KRAS signalling.42 Furthermore, WT1 loss decreases tumour burden in a mouse model of mutant KRAS‐driven cancer.42 Therefore, degrading WT1 protein by small molecule compounds such as degrasyn might inhibit oncogenic KRAS signalling.